OJCD  Vol.7 No.4 , December 2017
Expression of Mammaglobin and Carcinoembryonic Antigen in Peripheral Blood of Patients with Breast Cancer Using Real Time Polymerase Chain Reaction
Abstract: Background and Objectives: Breast cancer is among the most common causes of cancer related mortality in women worldwide. Early detection and prompt diagnosis of tumor is the first step to prevent cancer-related morbidity and mortality, and a comprehensive understanding of the involved molecular mechanisms can greatly help in this respect. Breast cancer, like many other types of cancer, is caused by a combination of genetic and epigenetic changes such as inactivation of tumor suppressor genes. Materials and Methods: This study was performed on 40 breast cancer patients and 40 healthy controls. Quantitative real time reverse transcription polymerase chain reaction (real time qRT-PCR) was used to assess the expression of carcinoembryonic antigen (CEA) and mammaglobin mRNA in the peripheral blood of patients and healthy controls. The two groups were compared using t-test. Results: The two groups were not significantly different in terms of the mean age. Twenty-nine out of 40 cancer patients were positive for CEA mRNA and its sensitivity was calculated to be 72.5%. Twelve out of 40 healthy controls were positive for CEA mRNA. Twenty-six out of 40 patients were positive for mammaglobin mRNA indicative of 65% sensitivity while only five out of 40 healthy controls were positive for mammaglobin mRNA. Conclusion: Both CEA and mammaglobin mRNA had high sensitivity in cancer patients; thus, they can be used for screening and early detection of breast cancer patients. Further studies with larger sample sizes are required to confirm the current findings.
Cite this paper: Khosravi, N. , Bahrami, N. , Khosravi, A. , Abedini, A. , Kiani, A. , Sharifynia, S. , Gharaeeyan, P. , Seifi, S. , Mohamadnia, A. (2017) Expression of Mammaglobin and Carcinoembryonic Antigen in Peripheral Blood of Patients with Breast Cancer Using Real Time Polymerase Chain Reaction. Open Journal of Clinical Diagnostics, 7, 103-112. doi: 10.4236/ojcd.2017.74011.

[1]   Key, T.J., Verkasalo, P.K. and Banks, E. (2001) Epidemiology of Breast Cancer. The Lancet Oncology, 2, 133-140.

[2]   Mitchell, P.S., Parkin, R.K., Kroh, E.M., Fritz, B.R., Wyman, S.K., Pogosova-Agadjanyan, E.L., et al. (2008) Circulating microRNAs as Stable Blood-Based Markers for Cancer Detection. Proceedings of the National Academy of Sciences, 105, 10513-10518.

[3]   Jemal, A., Siegel, R., Ward, E., Hao, Y., Xu, J., Murray, T., et al. (2008) Cancer Statistics, 2008. CA: A Cancer Journal for Clinicians, 58, 71-96.

[4]   Ban, K.A. and Godellas, C.V. (2014) Epidemiology of Breast Cancer. Surgical Oncology Clinics of North America, 23, 409-422.

[5]   Group EBCTC (2005) Effects of Chemotherapy and Hormonal Therapy for Early Breast Cancer on Recurrence and 15-Year Survival: An Overview of the Randomised Trials. The Lancet, 365, 1687-717.

[6]   Ekizoglu, S., Muslumanoglu, M., Dalay, N. and Buyru, N. (2012) Genetic Alterations of the WWOX Gene in Breast Cancer. Medical Oncology, 29, 1529-1535.

[7]   Stavros, A.T., Thickman, D., Rapp, C.L., Dennis, M.A., Parker, S.H. and Sisney, G.A. (1995) Solid Breast Nodules: Use of Sonography to Distinguish between Benign and Malignant Lesions. Radiology, 196, 123-134.

[8]   Chassevent, A., Jourdan, M.-L., Romain, S., Descotes, F., Colonna, M., Martin, P.-M., et al. (2001) S-Phase Fraction and DNA Ploidy in 633 T1T2 Breast Cancers. Clinical Cancer Research, 7, 909-917.

[9]   Etzioni, R., Urban, N., Ramsey, S., McIntosh, M., Schwartz, S., Reid, B., et al. (2003) The Case for Early Detection. Nature Reviews Cancer, 3, 243-252.

[10]   Radpour, R., Barekati, Z., Kohler, C., Lv, Q., Bürki, N., Diesch, C., et al. (2011) Hypermethylation of Tumor Suppressor Genes Involved in Critical Regulatory Pathways for Developing a Blood-Based Test in Breast Cancer. PLoS One, 6, e16080.

[11]   Radpour, R., Barekati, Z., Kohler, C., Holzgreve, W. and Zhong, X.Y. (2009) New Trends in Molecular Biomarker Discovery for Breast Cancer. Genetic Testing and Molecular Biomarkers, 13, 565-571.

[12]   Srinivas, P.R., Kramer, B.S. and Srivastava, S. (2001) Trends in Biomarker Research for Cancer Detection. The Lancet Oncology, 2, 698-704.

[13]   Bhatt, A.N., Mathur, R., Farooque, A., Verma, A. and Dwarakanath, B. (2010) Cancer Biomarkers-Current Perspectives. Indian Journal of Medical Research, 132, 129-149.

[14]   Bahrami, N., Gholami, M., Jamaati, H.R., Mohamadnia, A., Dargahi, H., Kazempour dizaji, M., Khosravi, A., Heshmatnia, J., Vahabi, P. and Bahrami, N.A. (2016) Expression of Two Essential mRNA Biomarker in the Peripheral Blood as Possible Biomarkers for Diagnosis of Non-Small Cell Lung Carcinoma. Minerva Pneumologica, 55, 31-36.

[15]   Jamaati, H., Bahrami, N., Abniki, M., Tabarsi, P., Farzanegan, B., Doroudinia, A., et al. (2016) Real-Time RT-PCR Detection of HCN4 and ADAM8 Genes in Ventilator-Associated Pneumonia Patients Hospitalized in Intensive Care Unit. Journal of Cellular and Molecular Anesthesia, 1, 163-167.

[16]   Khare, P.D., Shao-Xi, L., Kuroki, M., Hirose, Y., Arakawa, F., Nakamura, K., et al. (2001) Specifically Targeted Killing of Carcinoembryonic Antigen (CEA)-Expressing Cells by a Retroviral Vector Displaying Single-Chain Variable Fragmented Antibody to CEA and Carrying the Gene for Inducible Nitric Oxide Synthase. Cancer Research, 61, 370-375.

[17]   Ebeling, F., Stieber, P., Untch, M., Nagel, D., Konecny, G., Schmitt, U., et al. (2002) Serum CEA and CA 15-3 as Prognostic Factors in Primary Breast Cancer. British Journal of Cancer, 86, 1217-1222.

[18]   Zehentner, B.K. and Carter, D. (2004) Mammaglobin: A Candidate Diagnostic Marker for Breast Cancer. Clinical Biochemistry, 37, 249-257.

[19]   Fleming, T.P. and Watson, M.A. (2000) Mammaglobin, a Breast-Specific Gene, and Its Utility as a Marker for Breast Cancer. Annals of the New York Academy of Sciences, 923, 78-79.

[20]   Bossolasco, P., Ricci, C., Farina, G., Soligo, D., Pedretti, D., Scanni, A., et al. (2002) Detection of Micrometastatic Cells in Breast Cancer by RT-pCR for the Mammaglobin Gene. Cancer Detection and Prevention, 26, 60-63.

[21]   Grünewald, K., Haun, M., Urbanek, M., Fiegl, M., Müller-Holzner, E., Gunsilius, E., et al. (2000) Mammaglobin Gene Expression: A Superior Marker of Breast Cancer Cells in Peripheral Blood in Comparison to Epidermal-Growth-Factor Receptor and Cytokeratin-19. Laboratory Investigation, 80, 1071-1077.

[22]   Mohamadnia, A., Karimi, S., Yadegar Azari, R., Naji, S.A., Khosravi, A., Bahrami, N., et al. (2016) Expression of CK19 Gene in Patients with Lung Cancer and Its Comparison with Carcinoembryonic Antigen in Peripheral Blood. Journal of Payavard Salamat, 9, 459-468.

[23]   Jemal, A., Siegel, R., Ward, E., Hao, Y., Xu, J. and Thun, M.J. (2009) Cancer Statistics, 2009. CA: A Cancer Journal for Clinicians, 59, 225-249.

[24]   Ludwig, J.A. and Weinstein, J.N. (2005) Biomarkers in Cancer Staging, Prognosis and Treatment Selection. Nature Reviews Cancer, 5, 845-856.

[25]   Karimi, S., Mohamadnia, A., Nadji, S.A., Yadegarazari, R., Khosravi, A., Bahrami, N., et al. (2015) Expression of Two Basic mRNA Biomarkers in Peripheral Blood of Patients with Non-Small Cell Lung Cancer Detected by Real-Time rt-PCR, Individually and Simultaneously. Iranian Biomedical Journal, 19, 17.

[26]   Ghadimi, K., Bahrami, N., Fathi, M., Farzanegan, B., Naji, T., Emami, M., et al. (2017) Diagnostic Value of LunX mRNA and CEA mRNA Expression in Pleural Fluid of Patients with Non-Small Cell Lung Cancer. Minerva Pneumologica, 56.

[27]   Karimi, S., Bahrami, N., Sharifi, K., Daustany, M., Baghbani-Arani, F., Kazempour, M., et al. (2017) Investigating Gene Expression Level of MUC1 and CEA in Pleural Fluid of NSCLC Lung Cancer Patients with Real-Time RT-PCR Method. Minerva Pneumologica, 56, 18-24.

[28]   Moshref Behzad, N., Bahrami, N., Farzanegan, B., Fathi, M., Zareh Karizi, S. and Mohamadnia, A. (2017) Expression of CK19-mRNA and CEA-mRNA Biomarkers in Pleural Fluid of Patients with Non-Small Cell Lung Cancer. Minerva Pneumologica, 56.

[29]   Watson, M.A., Dintzis, S., Darrow, C.M., Voss, L.E., DiPersio, J., Jensen, R., et al. (1999) Mammaglobin Expression in Primary, Metastatic, and Occult Breast Cancer. Cancer Research, 59, 3028-3031.

[30]   Saccani, J.G., Bombardieri, E., Fontanesi, M., Becchi, G., Bocchi, P., Palli, D., et al. (1988) Plasma and Tissue CEA and TPA Markers in Operable Breast Cancer. Preliminary Results. Tumori, 74, 681-688.

[31]   Vizcarra, E., Lluch, A., Cibrian, R., Jarque, F. and Garcia-Conde, J. (1994) CA15.3, CEA and TPA Tumor Markers in the Early Diagnosis of Breast Cancer Relapse. Oncology, 51, 491-496.

[32]   Berois, N., Varangot, M., Aizen, B., Estrugo, R., Zarantonelli, L., Fernandez, P., et al. (2000) Molecular Detection of Cancer Cells in Bone Marrow and Peripheral Blood of Patients with Operable Breast Cancer. Comparison of CK19, MUC1 and CEA using RT-PCR. European Journal of Cancer, 36, 717-723.